GE HealthCare (GEHC) Stock Forecast, Price Target & Predictions
GEHC Stock Forecast
GE HealthCare stock forecast is as follows: an average price target of $93.88 (represents a 8.17% upside from GEHC’s last price of $86.79) and a rating consensus of 'Buy', based on 11 wall street analysts offering a 1-year stock forecast.
GEHC Price Target
The average price target for GE HealthCare (GEHC) is $93.88 based on 1-year price targets from 11 Wall Street analysts in the past 3 months, with a price target range of $110.00 to $76.00. This represents a potential 8.17% upside from GEHC's last price of $86.79.
GEHC Analyst Ratings
According to 11 Wall Street analysts, GE HealthCare's rating consensus is 'Buy'. The analyst rating breakdown for GEHC stock is 0 'Strong Buy' (0.00%), 7 'Buy' (63.64%), 4 'Hold' (36.36%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
GE HealthCare Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| May 30, 2024 | David Roman | Goldman Sachs | $87.00 | $78.45 | 10.90% | 0.24% |
| May 21, 2024 | Jason Bednar | Piper Sandler | $92.00 | $81.50 | 12.88% | 6.00% |
| May 01, 2024 | Anthony Petrone | Mizuho Securities | $105.00 | $77.74 | 35.07% | 20.98% |
| Apr 30, 2024 | Vijay Kumar | Evercore ISI | $96.00 | $76.24 | 25.92% | 10.61% |
| Apr 11, 2024 | Anthony Petrone | Mizuho Securities | $110.00 | $85.39 | 28.82% | 26.74% |
| Apr 01, 2024 | David Toung | Argus Research | $110.00 | $90.91 | 21.00% | 26.74% |
| Feb 12, 2024 | Graham Doyle | UBS | $88.00 | $83.17 | 5.81% | 1.39% |
| Jun 27, 2023 | Patrick Wood | Morgan Stanley | $76.00 | $77.17 | -1.52% | -12.43% |
| May 16, 2023 | Suraj Kalia | Oppenheimer | $97.00 | $77.00 | 25.97% | 11.76% |
The latest GE HealthCare stock forecast, released on May 30, 2024 by David Roman from Goldman Sachs, set a price target of $87.00, which represents a 10.90% increase from the stock price at the time of the forecast ($78.45), and a 0.24% increase from GEHC last price ($86.79).
GE HealthCare Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | - | 7 |
| Avg Price Target | - | - | $98.29 |
| Last Closing Price | $86.79 | $86.79 | $86.79 |
| Upside/Downside | -100.00% | -100.00% | 13.25% |
In the current month, the average price target of GE HealthCare stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to GE HealthCare's last price of $86.79. This month's average price target is down NaN% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| May 30, 2024 | Goldman Sachs | - | Neutral | Initialise |
| May 21, 2024 | Piper Sandler | Overweight | Overweight | Hold |
| Apr 30, 2024 | Evercore ISI | Outperform | Outperform | Hold |
| Apr 03, 2024 | Citigroup | Buy | Buy | Hold |
| Apr 01, 2024 | Argus Research | Buy | Buy | Hold |
| Feb 12, 2024 | UBS | Sell | Neutral | Upgrade |
| Nov 27, 2023 | UBS | - | Sell | Downgrade |
| Sep 19, 2023 | Citigroup | - | Buy | Initialise |
| Aug 16, 2023 | Wells Fargo | - | Overweight | Initialise |
| Jun 27, 2023 | Morgan Stanley | - | Equal-Weight | Initialise |
GE HealthCare's last stock rating was published by Goldman Sachs on May 30, 2024. The company Initialise its GEHC rating from "null" to "Neutral".
GE HealthCare Financial Forecast
GE HealthCare Revenue Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | $4.82B | $4.82B | $4.71B | $4.94B |
| Avg Forecast | $5.68B | $5.10B | $5.12B | $4.91B | $5.38B | $4.86B | $4.88B | $4.80B | $5.09B | $4.80B | $4.79B | $4.63B | $4.90B |
| High Forecast | $5.70B | $5.11B | $5.14B | $4.92B | $5.40B | $4.91B | $4.89B | $4.82B | $5.20B | $4.86B | $4.81B | $4.65B | $4.92B |
| Low Forecast | $5.64B | $5.07B | $5.09B | $4.88B | $5.35B | $4.83B | $4.85B | $4.77B | $5.03B | $4.75B | $4.76B | $4.61B | $4.87B |
| # Analysts | 4 | 3 | 4 | 3 | 5 | 8 | 5 | 2 | 4 | 8 | 5 | 4 | 4 |
| Surprise % | - | - | - | - | - | - | - | - | - | 1.00% | 1.01% | 1.02% | 1.01% |
GE HealthCare's average Quarter revenue forecast for Dec 23 based on 4 analysts is $5.09B, with a low forecast of $5.03B, and a high forecast of $5.20B. GEHC's average Quarter revenue forecast represents a 5.63% increase compared to the company's last Quarter revenue of $4.82B (Sep 23).
GE HealthCare EBITDA Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 4 | 3 | 4 | 3 | 5 | 8 | 5 | 2 | 4 | 8 | 5 | 4 | 4 |
| EBITDA | - | - | - | - | - | - | - | - | - | $617.00M | $570.00M | $839.00M | $777.00M |
| Avg Forecast | $1.05B | $943.53M | $947.43M | $908.18M | $995.64M | $900.58M | $902.70M | $888.94M | $943.05M | $889.50M | $887.26M | $857.96M | $907.20M |
| High Forecast | $1.05B | $946.83M | $950.75M | $911.36M | $999.12M | $909.84M | $905.86M | $892.05M | $963.43M | $900.10M | $890.36M | $860.96M | $910.38M |
| Low Forecast | $1.04B | $937.90M | $941.78M | $902.76M | $989.69M | $895.02M | $897.31M | $883.64M | $931.93M | $878.95M | $881.96M | $852.83M | $901.79M |
| Surprise % | - | - | - | - | - | - | - | - | - | 0.69% | 0.64% | 0.98% | 0.86% |
4 analysts predict GEHC's average Quarter EBITDA for Dec 23 to be $943.05M, with a high of $963.43M and a low of $931.93M. This is 52.84% upper than GE HealthCare's previous annual EBITDA (Sep 23) of $617.00M.
GE HealthCare Net Income Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 4 | 3 | 4 | 3 | 5 | 8 | 5 | 2 | 4 | 8 | 5 | 4 | 4 |
| Net Income | - | - | - | - | - | - | - | - | - | $886.00M | $707.00M | $383.00M | $554.00M |
| Avg Forecast | $648.10M | $528.84M | $519.77M | $467.78M | $595.79M | $482.90M | $448.38M | $416.20M | $491.36M | $411.75M | $398.96M | $363.76M | $896.85M |
| High Forecast | $651.05M | $531.24M | $522.13M | $469.91M | $598.49M | $492.02M | $450.42M | $418.09M | $495.95M | $420.89M | $400.77M | $365.41M | $900.93M |
| Low Forecast | $643.07M | $524.73M | $515.73M | $464.15M | $591.16M | $473.79M | $444.90M | $412.97M | $482.17M | $398.02M | $395.86M | $360.93M | $889.89M |
| Surprise % | - | - | - | - | - | - | - | - | - | 2.15% | 1.77% | 1.05% | 0.62% |
GE HealthCare's average Quarter net income forecast for Dec 23 is $491.36M, with a range of $482.17M to $495.95M. GEHC's average Quarter net income forecast represents a -44.54% decrease compared to the company's last Quarter net income of $886.00M (Sep 23).
GE HealthCare SG&A Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 4 | 3 | 4 | 3 | 5 | 8 | 5 | 2 | 4 | 8 | 5 | 4 | 4 |
| SG&A | - | - | - | - | - | - | - | - | - | $996.00M | $1.07B | $1.06B | $884.00M |
| Avg Forecast | $1.16B | $1.04B | $1.05B | $1.00B | $1.10B | $996.27M | $998.62M | $983.40M | $1.04B | $984.02M | $981.54M | $949.12M | $1.00B |
| High Forecast | $1.17B | $1.05B | $1.05B | $1.01B | $1.11B | $1.01B | $1.00B | $986.84M | $1.07B | $995.74M | $984.97M | $952.44M | $1.01B |
| Low Forecast | $1.16B | $1.04B | $1.04B | $998.68M | $1.09B | $990.12M | $992.66M | $977.53M | $1.03B | $972.34M | $975.68M | $943.45M | $997.61M |
| Surprise % | - | - | - | - | - | - | - | - | - | 1.01% | 1.09% | 1.12% | 0.88% |
GE HealthCare's average Quarter SG&A projection for Dec 23 is $1.04B, based on 4 Wall Street analysts, with a range of $1.03B to $1.07B. The forecast indicates a 4.74% rise compared to GEHC last annual SG&A of $996.00M (Sep 23).
GE HealthCare EPS Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 4 | 3 | 4 | 3 | 5 | 8 | 5 | 2 | 4 | 8 | 5 | 4 | 4 |
| EPS | - | - | - | - | - | - | - | - | - | $1.95 | $1.55 | $0.84 | $1.31 |
| Avg Forecast | $1.41 | $1.15 | $1.13 | $1.02 | $1.30 | $1.05 | $0.98 | $0.91 | $1.07 | $0.90 | $0.87 | $0.79 | $1.95 |
| High Forecast | $1.42 | $1.16 | $1.14 | $1.02 | $1.30 | $1.07 | $0.98 | $0.91 | $1.08 | $0.92 | $0.87 | $0.80 | $1.96 |
| Low Forecast | $1.40 | $1.14 | $1.12 | $1.01 | $1.29 | $1.03 | $0.97 | $0.90 | $1.05 | $0.87 | $0.86 | $0.79 | $1.94 |
| Surprise % | - | - | - | - | - | - | - | - | - | 2.17% | 1.78% | 1.06% | 0.67% |
According to 4 Wall Street analysts, GE HealthCare's projected average Quarter EPS for Dec 23 is $1.07, with a low estimate of $1.05 and a high estimate of $1.08. This represents a -45.10% decrease compared to GEHC previous annual EPS of $1.95 (Sep 23).
GE HealthCare Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| TDOC | Teladoc Health | $9.11 | $52.65 | 477.94% | Hold |
| GDRX | GoodRx | $7.59 | $14.57 | 91.96% | Buy |
| TXG | 10x Genomics | $21.41 | $30.20 | 41.06% | Hold |
| SDGR | Schrödinger | $19.62 | $27.33 | 39.30% | Buy |
| PGNY | Progyny | $24.82 | $34.50 | 39.00% | Hold |
| GEHC | GE HealthCare | $86.79 | $93.88 | 8.17% | Buy |
| VEEV | Veeva Systems | $214.80 | $229.50 | 6.84% | Buy |
| AMWL | American Well | $10.15 | $8.40 | -17.24% | Hold |
| DOCS | Doximity | $40.16 | $32.17 | -19.90% | Buy |
GEHC Forecast FAQ
Is GE HealthCare a good buy?
Yes, according to 11 Wall Street analysts, GE HealthCare (GEHC) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 7 'Buy' recommendations, accounting for 63.64% of GEHC's total ratings.
What is GEHC's price target?
GE HealthCare (GEHC) average price target is $93.88 with a range of $76 to $110, implying a 8.17% from its last price of $86.79. The data is based on 11 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will GE HealthCare stock go up soon?
According to Wall Street analysts' prediction for GEHC stock, the company can go up by 8.17% (from the last price of $86.79 to the average price target of $93.88), up by 26.74% based on the highest stock price target, and down by -12.43% based on the lowest stock price target.
Can GE HealthCare stock reach $130?
GEHC's average twelve months analyst stock price target of $93.88 does not support the claim that GE HealthCare can reach $130 in the near future.
What are GE HealthCare's analysts' financial forecasts?
GE HealthCare's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $19.92B (high $20.02B, low $19.8B), average EBITDA is $3.69B (high $3.71B, low $3.67B), average net income is $1.94B (high $1.96B, low $1.92B), average SG&A $4.08B (high $4.1B, low $4.06B), and average EPS is $4.23 (high $4.27, low $4.19). GEHC's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $20.8B (high $20.87B, low $20.67B), average EBITDA is $3.85B (high $3.86B, low $3.83B), average net income is $2.16B (high $2.17B, low $2.15B), average SG&A $4.26B (high $4.27B, low $4.23B), and average EPS is $4.72 (high $4.74, low $4.68).
Did the GEHC's actual financial results beat the analysts' financial forecasts?
Based on GE HealthCare's last annual report (Dec 2023), the company's revenue was $19.55B, beating the average analysts forecast of $19.32B by 1.18%. Apple's EBITDA was $2.44B, missing the average prediction of $3.58B by -31.94%. The company's net income was $3.1B, beating the average estimation of $1.67B by 86.33%. Apple's SG&A was $4.28B, beating the average forecast of $3.96B by 8.19%. Lastly, the company's EPS was $6.82, beating the average prediction of $3.63 by 87.92%. In terms of the last quarterly report (Sep 2023), GE HealthCare's revenue was $4.82B, beating the average analysts' forecast of $4.8B by 0.37%. The company's EBITDA was $617M, missing the average prediction of $889.5M by -30.64%. GE HealthCare's net income was $886M, beating the average estimation of $411.75M by 115.18%. The company's SG&A was $996M, beating the average forecast of $984.02M by 1.22%. Lastly, the company's EPS was $1.95, beating the average prediction of $0.897 by 117.38%